A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jodi L,Karnell

第一单位： Viela Bio, Gaithersburg, MD 20878, USA.

作者： Jodi L,Karnell ^[1] ; Marius,Albulescu ^[2] ; Stacey,Drabic ^[3] ; Liangwei,Wang ^[1] ; Rachel,Moate ^[4] ; Manuel,Baca ^[3] ; Vaheh,Oganesyan ^[3] ; Michele,Gunsior ^[1] ; Thomas,Thisted ^[3] ; Li,Yan ^[1] ; Jing,Li ^[5] ; Ximing,Xiong ^[3] ; Steven C,Eck ^[3] ; Melissa,de Los Reyes ^[3] ; Isharat,Yusuf ^[3] ; Katie,Streicher ^[3] ; Ulf,Müller-Ladner ^[6] ; David,Howe ^[4] ; Rachel,Ettinger ^[1] ; Ronald,Herbst ^[7] ; Jörn,Drappa ^[8]

作者单位： Viela Bio, Gaithersburg, MD 20878, USA. ^[1] AstraZeneca, Cambridge CB4 OWG, UK. ^[2] MedImmune, Gaithersburg, MD 20878, USA. ^[3] MedImmune, Granta Park, Cambridge CB21 6GH, UK. ^[4] MedImmune, San Francisco, CA 94080, USA. ^[5] Department of Rheumatology and Clinical Immunology, Campus Kerchoff, Justus-Liebig University Giessen, 61231 Bad Nauheim, Germany. ^[6] MedImmune, Gaithersburg, MD 20878, USA. herbstro@medimmune.com drappaj@vielabio.com. ^[7] Viela Bio, Gaithersburg, MD 20878, USA. herbstro@medimmune.com drappaj@vielabio.com. ^[8]